Affiliations: [a]
Department of Neurology, Qingdao Municipal Hospital, Weifang Medical University, Qingdao, China
| [b]
Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
| [c]
Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
Correspondence:
[*]
Correspondence to: Lan Tan and Jin-Tai Yu, Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, No. 5 Donghai Middle Road, Qingdao, Shandong Province 266071, China. E-mails: dr.tanlan@163.com (L. Tan) and yu-jintai@163.com (J.-T. Yu).
Abstract: The ATP-binding cassette transporter A7 (ABCA7) was identified as a known risk factor for Alzheimer’s disease (AD). However, the relation between ABCA7 and AD was still inconsistent across these studies. Here, our meta-analysis aimed at confirming the association of ABCA7 with AD. Finally, 16 case-control studies (63747 versus 85833) were retrieved from PubMed and other databases. Three common loci were confirmed to increase the risk of AD (rs3764650: OR = 1.20, 95% CI = 1.16–1.24; rs3752246: OR = 1.13,95% CI = 1.08–1.19; rs4147929: OR = 1.17, 95% CI = 1.10–1.24), but the associations varied among the different races. Furthermore, ABCA7 loss-of-function (LOF) mutations conferred a higher risk for AD than did the above variants (LOF: OR = 1.78, 95% = 1.43–2.22). In conclusion, ABCA7 genetic variants, especially the LOF mutations, were significantly associated with the risk of AD.
